title: Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants.
abstract: BACKGROUND
  Data is currently lacking in evaluating the weekly rates of recurrent venous thromboembolism (VTE) among patients receiving anticoagulants.
  
  
  OBJECTIVE
  To quantify the risk of VTE recurrence during the first 12 weeks after an index VTE event.
  
  
  METHODS
  Healthcare claims from Truven Health Analytics MarketScan database from January 2007 to June 2012 were analyzed. Adult patients with ≥1 diagnosis of VTE, ≥1 anticoagulant prescription dispensed within 7 days of the index VTE hospitalization discharge or outpatient/emergency room (ER) visit (index date), and a proportion of days covered ≥0.7 on the anticoagulant therapy during the 12 weeks post-discharge were included. The weekly risk of VTE recurrence was evaluated with the hazard function using the life-table method.
  
  
  RESULTS
  A total of 105,682 patients with a VTE were included. Mean age was 59 years and 49% were female. The risk of VTE recurrence was at its highest during the first and second weeks, at 0.78% and 0.83%, respectively. The risk remained high during Weeks 3, 4, and 5 with risks of VTE recurrence of 0.63%, 0.52%, and 0.39%, respectively. The risk of VTE recurrence stabilized around Week 7, with risks of 0.26%, 0.22%, 0.20%, 0.25%, 0.23%, and 0.23% for Weeks 7, 8, 9, 10, 11 and 12, respectively.
  
  
  CONCLUSIONS
  Claims data may have contained inaccuracies. During hospitalizations it was not possible to assess anticoagulant use or a VTE recurrence occurring in the same hospitalization as the index VTE event.
  
  
  CONCLUSIONS
  This analysis suggests that the risk of VTE recurrence remains high in the early weeks after an index VTE among patients receiving anticoagulants.
authors.affiliation: Groupe d'analyse Ltée , Montréal, QC , Canada.
authors.forename: François
authors.initials: F
authors.lastname: Laliberté
authors.forename: Craig I
authors.initials: CI
authors.lastname: Coleman
authors.forename: Brahim
authors.initials: B
authors.lastname: Bookhart
authors.forename: Patrick
authors.initials: P
authors.lastname: Lefebvre
authors.forename: Michel
authors.initials: M
authors.lastname: Cloutier
authors.forename: C V
authors.initials: CV
authors.lastname: Damaraju
authors.forename: Jeffery R
authors.initials: JR
authors.lastname: Schein
authors.forename: Scott
authors.initials: S
authors.lastname: Kaatz
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D016208:Databases, Factual; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000188:drug therapy*; D012008:Recurrence; D012189:Retrospective Studies; D012306:Risk; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000188:drug therapy*; D020246:Venous Thrombosis / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants
keywords: Anticoagulants; Recurrence; Risk; Venous thromboembolism